GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Curis, Inc. (CRIS) [hlAlert]

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and
regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.
( Total: 13 Current Stock Recommendations )
Curis, Inc.   (13)
Hold Buy 92%
Related companies
China Biologic ...   (4)
Buy 100%
ATHERSYS INC   (7)
Buy 100%
ACURA PHARMACEUTICAL   (2)
Buy 100%
BioSpecifics ...   (5)
Buy 100%
Derma Sciences, Inc.   (2)
Buy 100%
Tenax Therapeutics ...   (2)
Buy 100%
ARCA BIOPHARMA INC.   (1)
Buy 100%
PROLOR Biotech, Inc.   (5)
Buy 100%
Opko Health Inc   (2)
Buy 100%
Nutraceutical ...   (1)
Buy 100%
Filter by Gains:   
  
Rating:
Buy CRIS
down 31.69 %

Rating:
Buy CRIS
down 31.69 %
Curis, Inc. (CRIS) rated Buy with price target $6 by ROTH Capital
Wednesday,  Jan 21, 2015  1:25 PM ET

Rating:
Buy CRIS
down 31.31 %
Curis, Inc. (CRIS) rated Outperform by Wedbush
Friday,  Dec 6, 2013  8:25 AM ET

Rating:
Buy CRIS
down 44.69 %

Rating:
Buy CRIS
down 41.72 %

Rating:
Hold CRIS
Curis, Inc. (CRIS) rated Hold by Stifel Nicolaus
Wednesday,  Nov 14, 2012  8:25 AM ET

Rating:
Buy CRIS
down 23.78 %

Rating:
Buy CRIS
up 10.13 %

Rating:
Buy CRIS
down 30.55 %

Rating:
Buy CRIS
down 23.78 %

Rating:
Buy CRIS
down 18.83 %
Curis, Inc. (CRIS) rated Buy with price target $8.50 by MLV Capital
Thursday,  Sep 22, 2011  10:25 AM ET

Rating:
Buy CRIS
up 10.13 %

Rating:
Buy CRIS
up 10.13 %

Rating:
Buy CRIS
down 31.69 %

Rating:
Buy CRIS
down 31.69 %

Your Recent Stocks
SymbolLastChange
CRIS 1.92 down  -23.20 %

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy